Cybin Expands Clinical Trial Sites for CYB003, Advancing Psychedelic Therapy for Major Depressive Disorder

Cybin Inc., a clinical-stage biopharmaceutical company, has announced the expansion of its strategic partnership agreements to include 18 additional U.S. clinical sites for its multinational Phase 3 trial of CYB003. This next-generation psychedelic-based therapy targets major depressive disorder (MDD), a condition affecting millions worldwide. The APPROACH study, a critical component of Cybin’s PARADIGM program, is set to expand to approximately 45 sites globally. This expansion is designed to leverage site-specific expertise, ensuring protocol consistency and accelerating trial timelines. Among the notable partners are CenExel iResearch Atlanta and Cedar Clinical Research, both recognized for their contributions to clinical research.

The development of CYB003 represents a significant step forward in the treatment of MDD, offering hope for a new and innovative therapeutic option. Cybin’s approach to mental healthcare, supported by a network of world-class partners and scientists, underscores the potential of psychedelic-based compounds to address unmet needs in mental health treatment. The company’s pipeline also includes CYB004, a proprietary deuterated DMT molecule aimed at treating generalized anxiety disorder, further highlighting its commitment to revolutionizing mental healthcare.

For more details on Cybin’s groundbreaking work and the full press release, visit https://ibn.fm/453yc. Cybin’s efforts in advancing psychedelic-based therapies could have profound implications for the mental health industry, offering new avenues for treatment and potentially improving the lives of individuals suffering from mental health conditions.